Helical Irradiation of Total Skin (HITS) for Cutaneous Lymphoma

Status Active, not recruiting

Clinical Trial Summary

Radiation therapy, Total skin electron beam therapy (TSEBT), achieves a high response rate and is an effective treatment for cutaneous T-cell lymphoma affecting the superficial region. One the most widely used TSEBT techniques consists of six dual fields initially developed at Stanford University. However, deviations occur from the prescription dose up to 40% and the surface dose inhomogeneity as much as 90% in body areas such as the perineum and eyelid.

Helical tomotherapy (HT) has advantages in irradiating extended volumes with treatment length of up to 160 cm, continuously in a helical pattern without the need for field junction. Using HT, an image-guided intensity-modulated radiotherapy, to replace conventional TSEBT technique to increase dose delivery and decrease toxicities possibly. Recently, we published the possibility of helical irradiation of the total skin (HITS) by physical proving and showed the clinical results of HITS successfully for a woman with T cell lymphoma failure by chemotherapy, topic UV irradiation and local radiotherapy (RT) to overcome the surface dose inhomogeneity by conventional RT.

Here, investigators will enroll the stage I-IV cutaneous T-cell lymphoma (CTCL) of International Society Cutaneous Lymphomas (ISCL)/U.S. Cutaneous Lymphoma Consortium (USCLC)/European Organization for Research & Treatment of Cancer (EORTC), patients who are candidates for TSEBT by recommendation of National Comprehensive Cancer Network Guidelines (Version 4.2011, Mycosis fungoid/Sezary syndrome) or who are refractory or not feasible to the topic UV irradiation, Interferon alpha, psoralen plus ultraviolet A photochemotherapy, and Accutane® (Isotretinoin) or chemotherapy to receive HITS to replace TSEBT. Additionally, we will compare the advantages and disadvantages between the plan of HT and conventional RT for TSEBT.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02039895
Study type	Interventional
Source	Far Eastern Memorial Hospital
Contact
Status	Active, not recruiting
Phase	N/A
Start date	January 2014
Completion date	December 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00341939` - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed	`NCT00038025` - A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies	Phase 2
Not yet recruiting	`NCT02881749` - Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides	Phase 2
Completed	`NCT00744991` - A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma	Phase 2
Completed	`NCT00099593` - Immunization Against Tumor Cells in Sezary Syndrome	Phase 2
Completed	`NCT02593045` - Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)	Phase 1
Recruiting	`NCT00779896` - Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study	Phase 1/Phase 2
Recruiting	`NCT00177268` - Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Withdrawn	`NCT00969085` - Trial of Curcumin in Cutaneous T-cell Lymphoma Patients	Phase 2
Completed	`NCT01728805` - Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL	Phase 3
Completed	`NCT00412997` - LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma	Phase 1
Completed	`NCT00254332` - Effect of Denileukin Diftitox on Immune System in CTCL Patients	N/A
Recruiting	`NCT04296786` - Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study	Phase 2
Recruiting	`NCT06285370` - A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy	Phase 4
Completed	`NCT00071084` - Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.	Phase 2
Completed	`NCT00896493` - Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma	Phase 2
Terminated	`NCT00699296` - Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma	Phase 2
Completed	`NCT02676778` - Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma	Phase 2
Terminated	`NCT02061449` - Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma	Phase 1
Completed	`NCT01134341` - Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Helical Irradiation of Total Skin (HITS) for Cutaneous Lymphoma — HITS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms